SEPTIN9 and neoplasm: Compared to molecular markers such as methylation of SEPT9 [19, 65, 66] in tumor-derived cell-free DNA, microRNA signatures in various biofluids (plasma, serum, or stool) [67–69], genetic [70, 71], or proteomic markers [72–74] performance of methylation markers in stool DNA for detecting various stages of CRC seems poorer.